Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
55
CRL Quote, Financials, Valuation and Earnings
Last price:
$202.04
Seasonality move
:
6.32%
Day range:
$200.90 - $203.63
52-week range:
$91.86 - $205.00
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
2.52x
P/B ratio:
2.92x
Volume:
300.9K
Avg. volume:
744.5K
1-year change:
10.12%
Market cap:
$9.9B
Revenue:
$4B
EPS (TTM):
-$1.56
Analysts' Opinion
-
Consensus RatingCharles River Laboratories International, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $197.33, Charles River Laboratories International, Inc. has an estimated downside of -2.3% from its current price of $201.98.
-
Price Target UpsideAccording to analysts, the highest upside price target is $230.00 representing -100% upside increase from its current price of $201.98.
Fair Value
-
According to the consensus of 17 analysts, Charles River Laboratories International, Inc. has -2.3% downside to fair value with a price target of $197.33 per share.
CRL vs. S&P 500
-
Over the past 5 trading days, Charles River Laboratories International, Inc. has overperformed the S&P 500 by 0% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Charles River Laboratories International, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Charles River Laboratories International, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Charles River Laboratories International, Inc. reported revenues of $1B.
Earnings Growth
-
Charles River Laboratories International, Inc. earnings have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Charles River Laboratories International, Inc. reported earnings per share of $1.10.
Enterprise value:
12.4B
EV / Invested capital:
--
Price / LTM sales:
2.52x
EV / EBIT:
25.83x
EV / Revenue:
3.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
22.83x
Price / Operating cash flow:
18.64x
Enterprise value / EBITDA:
13.67x
Gross Profit (TTM):
$1.2B
Return On Assets:
-1.04%
Net Income Margin (TTM):
-1.98%
Return On Equity:
-2.28%
Return On Invested Capital:
-1.27%
Operating Margin:
15.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.2B | $4.1B | $4B | $1B | $1B | |
| Gross Profit | $1.4B | $1.3B | $1.2B | $335.4M | $324.7M | |
| Operating Income | $664.5M | $611.2M | $480.3M | $148.4M | $151.1M | |
| EBITDA | $975.7M | $951.4M | $907.5M | $236.5M | $236.2M | |
| Diluted EPS | $9.23 | $8.10 | -$1.56 | $1.33 | $1.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B | |
| Total Assets | $7.1B | $7.4B | $7.6B | $8B | $7.5B | |
| Current Liabilities | $983.8M | $1B | $993.8M | $1B | $1.1B | |
| Total Liabilities | $4.6B | $4.7B | $4.3B | $4.2B | $4.1B | |
| Total Equity | $2.5B | $2.7B | $3.4B | $3.8B | $3.5B | |
| Total Debt | $3.2B | $3.3B | $2.9B | $2.8B | $2.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $697.7M | $796.2M | $749.5M | $251.8M | $213.8M | |
| Cash From Investing | -$280.4M | -$407.4M | -$211.8M | -$21.3M | -$33.7M | |
| Cash From Financing | -$458M | -$351.5M | -$560.7M | -$207.5M | -$152.6M | |
| Free Cash Flow | $368.5M | $560.5M | $543.7M | $213.1M | $178.2M | |
CRL
Sector
Market Cap
$9.9B
$27.9M
Price % of 52-Week High
98.53%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
5.22%
-1.55%
1-Year Price Total Return
10.12%
-17.49%
Beta (5-Year)
1.633
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$201.10
200-day SMA
Buy
Level
$158.33
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$194.07
Relative Strength Index (RSI14)
Buy
Level
67.72
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-15.9788
50-day SMA
Buy
Level
$183.28
MACD (12, 26)
Buy
Level
6.94
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
--
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5976)
Buy
CA Score
(Annual)
Level (-0.1727)
Buy
Beneish M-Score
(Annual)
Level (-2.98)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (9.1822)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Stock Forecast FAQ
In the current month, CRL has received 10 Buy ratings 7 Hold ratings, and 0 Sell ratings. The CRL average analyst price target in the past 3 months is $197.33.
-
Where Will Charles River Laboratories International, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Charles River Laboratories International, Inc. share price will drop to $197.33 per share over the next 12 months.
-
What Do Analysts Say About Charles River Laboratories International, Inc.?
Analysts are divided on their view about Charles River Laboratories International, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Charles River Laboratories International, Inc. is a Sell and believe this share price will rise from its current level to $155.00.
-
What Is Charles River Laboratories International, Inc.'s Price Target?
The price target for Charles River Laboratories International, Inc. over the next 1-year time period is forecast to be $197.33 according to 17 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is CRL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Charles River Laboratories International, Inc. is a Buy. 10 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRL?
You can purchase shares of Charles River Laboratories International, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Charles River Laboratories International, Inc. shares.
-
What Is The Charles River Laboratories International, Inc. Share Price Today?
Charles River Laboratories International, Inc. was last trading at $202.04 per share. This represents the most recent stock quote for Charles River Laboratories International, Inc.. Yesterday, Charles River Laboratories International, Inc. closed at $201.98 per share.
-
How To Buy Charles River Laboratories International, Inc. Stock Online?
In order to purchase Charles River Laboratories International, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CRL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRL
Sector
P/E ratio
913.13x
23.75x
PEG ratio
--
-0.01x
P/B ratio
2.92x
1.81x
Price / LTM sales
2.52x
1.59x
Growth Metrics
CRL
Sector
Revenue growth
-0.49%
4.6%
Earnings growth
-17.3%
10.88%
Revenue (5-year growth)
9.09%
6.45%
Earnings forecast
$2.35
-$0.21
Profitability
CRL
Sector
Profitability FY 2024
$1.3B
$3.6M
Return on invested capital
-1.27%
-31.84%
Return on assets
-1.04%
-27.96%
Return on equity
-2.28%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
18
Estimated Next Earnings Date
Feb
4
Balance Sheet
CRL
Sector
Total cash
$207.7M
$26.3M
Short term investments
--
$25.7M
Total assets
$7.5B
$76.9M
Long term debt
$2.6B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
